252 related articles for article (PubMed ID: 35953822)
1. Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer.
Wang C; Chen Y; Xinpeng Y; Xu R; Song J; Ruze R; Xu Q; Zhao Y
BMC Cancer; 2022 Aug; 22(1):879. PubMed ID: 35953822
[TBL] [Abstract][Full Text] [Related]
2. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer.
Chen Y; Wang C; Song J; Xu R; Ruze R; Zhao Y
Front Immunol; 2021; 12():758004. PubMed ID: 34887861
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.
Zou W; Li L; Wang Z; Jiang N; Wang F; Hu M; Liu R
Bioengineered; 2021 Dec; 12(1):9006-9020. PubMed ID: 34654352
[TBL] [Abstract][Full Text] [Related]
4. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
5. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
6. A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer.
Xiao M; Liang X; Yan Z; Chen J; Zhu Y; Xie Y; Li Y; Li X; Gao Q; Feng F; Fu G; Gao Y
Front Immunol; 2022; 13():803962. PubMed ID: 35222383
[TBL] [Abstract][Full Text] [Related]
7. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma.
Tang P; Qu W; Wu D; Chen S; Liu M; Chen W; Ai Q; Tang H; Zhou H
J Immunol Res; 2021; 2021():3821055. PubMed ID: 34993253
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
9. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer.
Song J; Ruze R; Chen Y; Xu R; Yin X; Wang C; Xu Q; Zhao Y
BMC Cancer; 2022 Aug; 22(1):894. PubMed ID: 35974300
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer.
Wei C; Liang Q; Li X; Li H; Liu Y; Huang X; Chen X; Guo Y; Li J
J Cell Biochem; 2019 Sep; 120(9):14916-14927. PubMed ID: 31016791
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
14. Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.
Zhuang H; Chen X; Wang Y; Huang S; Chen B; Zhang C; Hou B
Cancer Immunol Immunother; 2022 Mar; 71(3):601-612. PubMed ID: 34279685
[TBL] [Abstract][Full Text] [Related]
15. Prognostic alternative splicing signature reveals the landscape of immune infiltration in Pancreatic Cancer.
Wang L; Bi J; Li X; Wei M; He M; Zhao L
J Cancer; 2020; 11(22):6530-6544. PubMed ID: 33046974
[No Abstract] [Full Text] [Related]
16. A novel CD8
Lin F; Ke ZB; Xue YT; Chen JY; Cai H; Lin YZ; Li XD; Wei Y; Xue XY; Xu N
Inflamm Res; 2023 Aug; 72(8):1665-1687. PubMed ID: 37578544
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
18. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
Front Immunol; 2021; 12():728062. PubMed ID: 34691034
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
20. A Four Autophagy-Related Gene-Based Prognostic Signature for Pancreatic Cancer.
Zhou Q; Chen X; Chen Q; Liu H; Hao L
Crit Rev Eukaryot Gene Expr; 2021; 31(4):89-100. PubMed ID: 34587439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]